FilingSEC EDGAR6-K
Addex Therapeutics Announces Completion of Phase 1 Clinical Studies by Spin-out Neurosterix
· SEC accepted
StagePhase 1 Completed
Filing content
Neurosterix, in which Addex holds a 20% equity interest, has completed Phase 1 clinical studies for its schizophrenia drug candidate NTX-253 and plans to advance to Phase 2.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…